BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
BioLineRx enters into $5.6M royalty Monetization transaction with Soleus Capital (1.00a, 0.00)
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx, Hemispherian present two GLIX1 posters at 31st SNO Annual Meeting (1.00a, 0.00)
Powered by FactSet Research Systems Inc.